Search results
Greeley girl fights rare, life-threatening blood disorder with positive attitude, deep bonds with...
Greeley Tribune· 5 days agoAubrie Dawson experienced a roller coaster of health scares that put her in a lot of...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Benzinga· 4 days agoSUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 4 days agoProgression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf;...
New Gene Tests Can Predict if a Drug Will Work for a Patient
Medscape· 6 days agoWhat if there were tests that could tell you whether the following drugs were a good match for your...
Raleigh facility plays key role in $245M collaboration - Triangle Business Journal
The Business Journals· 7 days agoAstraZeneca (Nasdaq: AZN) has invested $245 million in Cellectis (Nasdaq: CLLS), a clinical-stage...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 22 hours agoLive from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% PR Newswire SUZHOU, China and ROCKVILLE, Md., June 4, 2024 SUZHOU, China ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoLive from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...
Experimental Therapy Shows Promise in Pancreatic C | Newswise
Newswise· 7 days agoWASHINGTON --- Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic ...
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial
MedPage Today· 5 days agoReplacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoLive from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC PR Newswire SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 SUZHOU, China ...